Search research articles
Contact Us
Filters
Showing results (21-30 of 84) with videos related to
Page
of 9
Sort By:
Molecular and Cellular Biology
|
September 19, 2007
Biochemical and functional characterization of germ line KRAS mutations
Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 3, 2009
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells
Paolo Salerno, Valentina De Falco, Anna Tamburrino, et al.
Endocrine Reviews
|
February 16, 2017
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells
Paolo Salerno, Valentina De Falco, Anna Tamburrino, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2008
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cédric Louvet, Gregory L Szot, Jiena Lang, et al.
Cancer Research
|
November 20, 2013
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy
Stephen Mok, Richard C Koya, Christopher Tsui, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
Michael S Gordon, Richard D Carvajal, Alexander Spira, et al.
Haematologica
|
January 28, 2021
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 12, 2016
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
Ross A Okimoto, Luping Lin, Victor Olivas, et al.
Nature Communications
|
February 9, 2016
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
Yasmine White, Aditi Bagchi, Jessica Van Ziffle, et al.
Blood
|
August 28, 2004
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
Peter G Smith, Fengfei Wang, Kathryn N Wilkinson, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 84) with videos related to
Sort By:
Page
of 9
Molecular and Cellular Biology
|
September 19, 2007
Biochemical and functional characterization of germ line KRAS mutations
Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 3, 2009
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells
Paolo Salerno, Valentina De Falco, Anna Tamburrino, et al.
Endocrine Reviews
|
February 16, 2017
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells
Paolo Salerno, Valentina De Falco, Anna Tamburrino, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2008
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cédric Louvet, Gregory L Szot, Jiena Lang, et al.
Cancer Research
|
November 20, 2013
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy
Stephen Mok, Richard C Koya, Christopher Tsui, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
Michael S Gordon, Richard D Carvajal, Alexander Spira, et al.
Haematologica
|
January 28, 2021
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 12, 2016
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
Ross A Okimoto, Luping Lin, Victor Olivas, et al.
Nature Communications
|
February 9, 2016
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
Yasmine White, Aditi Bagchi, Jessica Van Ziffle, et al.
Blood
|
August 28, 2004
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
Peter G Smith, Fengfei Wang, Kathryn N Wilkinson, et al.
Page
of 9